摘要
目的分析多西他赛治疗前列腺癌的效果及其对患者P糖蛋白(P-gp)表达的影响。方法选取我院收治的前列腺癌患者78例,按随机数字法分为两组,对照组采用比卡鲁胺治疗,研究组采用多西他赛联合比卡鲁胺治疗,比较两组患者的治疗效果以及P-gp的表达。结果研究组治疗有效率为92.3%,明显高于对照组的38.5%(P<0.05);研究组不良反应发生率为23.1%,对照组为25.6%,差异无统计学意义(P>0.05);治疗前两组患者的生活质量无明显差异(P>0.05),治疗后均有所提高,且研究组躯体、生理、心理和社会功能评分明显高于对照组(P<0.05);治疗后,研究组P-gp表达阳性患者明显少于对照组(P<0.05)。结论针对前列腺癌患者应用多西他赛联合比卡鲁胺治疗,可更有效地控制和缓解病情,提高生活质量,改善P-gp表达。
Objective To explore the efficacy of docetaxel in the treatment of prostate cancer and its effect on the expression of P-glycoprotein(P-gp)in the patients.Methods A total of 78 cases of prostate cancer treated in our hospital were selected and divided into two groups according to the random number method.The control group got bicalutamide treatment,and the study group got docetaxel combined with bicalutamide treatment.The efficacy of patients and the effects on the expression of P-gp in the patients were compared between the two groups.Results After treatment,the effective rate of the study group was 92.3%,and it was significantly higher than that of the control group(38.5%)(P<0.05).In the course of treatment,the incidence of adverse reactions in the study group and the control group were 23.1% and 25.6% respectively,and there was no significant difference between the two groups(P>0.05).Before treatment,there was no significant difference in quality of life between the two groups(P>0.05).But after treatment,the scores of physical,physiology,psychology and social functions in the study group were significantly higher than those in the control group(P<0.05).After the treatment was completed,there were obviously less patients with positive expression of P-gp in the study group than in the control group(P<0.05).Conclusion Docetaxel combined wtih bicalutamide treatment can effectively control and alleviate prostate cancer for patients,and improve the quality of life.It also could improve the expression of P-gp,and do not increase adverse reactions.
作者
张冲
杨鹏
刘振湘
张淑芳
吕蔡
ZHANG Chong;YANG Peng;LIU Zhenxiang;ZHANG Shufang;LV Cai(Urinary Surgical Department,the Affiliated Haikou Hospital of Xiangya School of Medicine,Central South University,Haikou,Hainan,570208,China)
出处
《肿瘤药学》
CAS
2018年第5期779-782,共4页
Anti-Tumor Pharmacy
基金
海南省卫生厅医学科研重点课题(琼卫2013重点-04)